Profile data is unavailable for this security.
About the company
Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.
- Revenue in INR (TTM)21.92bn
- Net income in INR3.60bn
- Incorporated1956
- Employees2.17k
- LocationSanofi India Ltd54/ASir Mathuradas Vasanji RoadAndheri EastMUMBAI 400072IndiaIND
- Phone+91 2 228032000
- Fax+91 2 228032846
- Websitehttps://www.sanofiindialtd.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F D C Ltd | 20.72bn | 3.17bn | 80.46bn | 6.66k | 25.53 | 3.51 | 22.24 | 3.88 | 19.36 | 19.36 | 126.27 | 140.76 | 0.824 | 2.16 | 12.48 | 3,112,058.00 | 12.59 | 12.05 | 14.46 | 13.73 | 65.35 | 61.54 | 15.27 | 15.85 | 2.49 | 72.53 | 0.0087 | 1.09 | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Procter & Gamble Health Ltd | 11.60bn | 2.18bn | 85.32bn | 1.34k | 39.20 | -- | 34.90 | 7.36 | 131.10 | 131.10 | 698.14 | -- | -- | -- | -- | 8,680,689.00 | -- | -- | -- | -- | 71.42 | -- | 18.77 | -- | -- | 441.58 | -- | -- | -6.37 | -- | -12.42 | -- | -- | -- |
| Shilpa Medicare Ltd | 12.15bn | 610.83m | 87.74bn | 931.00 | 134.61 | 3.77 | 51.63 | 7.22 | 6.67 | 6.67 | 132.68 | 238.05 | 0.3969 | 1.24 | 3.40 | 13,047,900.00 | 2.00 | 2.84 | 2.44 | 3.65 | 66.38 | 60.08 | 5.04 | 7.03 | 1.08 | 1.79 | 0.1746 | 10.76 | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Blue Jet Healthcare Ltd | 7.22bn | 1.68bn | 91.62bn | 447.00 | 54.58 | 9.92 | 47.83 | 12.69 | 9.68 | 9.68 | 41.61 | 53.27 | 0.6732 | 1.97 | 3.46 | 16,149,080.00 | 15.66 | -- | 19.57 | -- | 55.65 | -- | 23.26 | -- | 2.51 | 131.95 | 0.0012 | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| Akums Drugs and Pharmaceuticals Ltd | 40.79bn | 2.78bn | 105.78bn | 7.39k | 36.80 | 3.63 | 25.32 | 2.59 | 18.26 | 18.26 | 272.23 | 185.07 | 1.04 | 3.77 | 3.94 | 5,521,446.00 | 7.20 | -- | 11.08 | -- | 37.76 | -- | 6.95 | -- | 1.59 | 2.23 | 0.1571 | -- | 14.32 | -- | -104.25 | -- | -- | -- |
| Sanofi Consumer Healthcare India Ltd | -100.00bn | -100.00bn | 110.30bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Strides Pharma Science Ltd | 44.10bn | 1.77bn | 130.35bn | 3.07k | 73.75 | 5.73 | 35.07 | 2.96 | 19.22 | 25.15 | 479.84 | 247.16 | 0.7155 | 1.50 | 3.57 | 14,389,290.00 | 2.79 | -1.68 | 5.43 | -2.97 | 60.19 | 51.39 | 3.91 | -3.36 | 0.6355 | 1.52 | 0.5103 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Glenmark Life Sciences Ltd | 22.05bn | 4.24bn | 133.89bn | 2.01k | 31.70 | 5.27 | 27.85 | 6.07 | 34.47 | 34.47 | 179.44 | 207.17 | 0.7304 | 1.46 | 2.79 | 10,947,850.00 | 14.03 | 18.28 | 16.69 | 29.99 | 54.92 | 53.40 | 19.21 | 20.23 | 3.03 | 380.55 | 0.0063 | 26.37 | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Granules India Ltd | 44.78bn | 4.87bn | 139.37bn | 4.12k | 28.64 | 4.07 | 19.96 | 3.11 | 20.08 | 20.08 | 184.59 | 141.41 | 0.8372 | 1.36 | 5.14 | 10,863,290.00 | 9.11 | 10.68 | 14.05 | 16.18 | 59.39 | 48.83 | 10.88 | 11.82 | 0.7152 | 6.88 | 0.2425 | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Marksans Pharma Ltd | 23.79bn | 3.47bn | 143.00bn | 2.00k | 41.18 | 6.27 | 33.22 | 6.01 | 7.66 | 7.66 | 52.53 | 50.34 | 0.9105 | 1.65 | 4.75 | 11,893,400.00 | 13.30 | 14.62 | 15.78 | 18.52 | 55.32 | 50.52 | 14.61 | 14.03 | 2.97 | 31.25 | 0.0792 | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Sanofi India Ltd | 21.92bn | 3.60bn | 143.02bn | 2.17k | 39.72 | -- | 35.99 | 6.52 | 156.36 | 199.60 | 951.86 | -- | -- | -- | -- | 10,083,720.00 | -- | 22.42 | -- | 30.21 | 53.94 | 55.52 | 16.43 | 21.03 | -- | 348.40 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Caplin Point Laboratories Ltd | 18.31bn | 4.94bn | 150.24bn | 859.00 | 30.54 | 5.91 | 26.84 | 8.21 | 64.73 | 64.73 | 240.10 | 334.54 | 0.6861 | 2.28 | 3.40 | 21,312,920.00 | 18.62 | 19.83 | 21.36 | 22.82 | 58.72 | 53.38 | 27.14 | 25.39 | 5.07 | 932.86 | 0.0009 | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
| Astrazeneca Pharma India Ltd | 14.85bn | 819.20m | 161.43bn | 940.00 | 197.08 | 23.76 | 157.31 | 10.87 | 32.76 | 32.76 | 593.93 | 271.74 | 1.27 | 2.52 | 10.63 | 15,792,680.00 | 6.99 | 11.78 | 11.44 | 19.62 | 44.88 | 54.64 | 5.52 | 10.27 | 1.44 | 134.82 | 0.0246 | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Jubilant Pharmova Ltd | 69.20bn | 5.93bn | 176.11bn | 995.00 | 29.74 | 2.96 | 18.22 | 2.54 | 37.38 | 37.38 | 436.41 | 375.04 | 0.5934 | 1.75 | 8.15 | 69,544,720.00 | 5.05 | 2.96 | 6.01 | 3.55 | 68.50 | 68.47 | 8.51 | 5.13 | 1.20 | 2.51 | 0.342 | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Neuland Laboratories Ltd. | 15.28bn | 2.80bn | 190.57bn | 1.65k | 68.14 | 13.73 | 55.46 | 12.47 | 217.98 | 217.98 | 1,191.20 | 1,081.52 | 0.847 | 2.14 | 4.85 | 9,273,565.00 | 15.50 | 9.25 | 20.03 | 12.71 | 52.14 | 47.81 | 18.30 | 11.99 | 1.40 | 31.56 | 0.0728 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Eris Lifesciences Ltd | 24.98bn | 3.48bn | 200.59bn | 3.08k | 57.62 | 7.23 | 32.20 | 8.03 | 25.57 | 25.57 | 183.35 | 203.74 | 0.4585 | 2.90 | 5.96 | 8,110,753.00 | 6.73 | 13.42 | 8.39 | 16.80 | 77.03 | 79.98 | 14.69 | 24.96 | 0.8599 | 3.41 | 0.4626 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
Data as of Nov 26 2024. Currency figures normalised to Sanofi India Ltd's reporting currency: Indian Rupee INR
21.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2024 | 1.37m | 5.95% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Oct 2024 | 892.72k | 3.88% |
| SBI Funds Management Ltd.as of 31 Oct 2024 | 714.65k | 3.10% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Oct 2024 | 605.56k | 2.63% |
| Bajaj Allianz Life Insurance Co. Ltd.as of 30 Jun 2024 | 368.45k | 1.60% |
| The Vanguard Group, Inc.as of 31 Oct 2024 | 343.10k | 1.49% |
| HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Jun 2024 | 320.72k | 1.39% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 168.77k | 0.73% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 123.32k | 0.54% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 85.52k | 0.37% |
More ▼
Data from 30 Jun 2024 - 21 Nov 2024Source: FactSet Research Systems Inc.
